Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3440-3448

  Hanley, Kathryn A ^a   Manlucu, Luella R ^a   Manipon, Gracielle G ^a   Hanson, Christopher T ^a   Whitehead, Stephen S ^a   Murphy, Brian R ^a   Blaney Jr , Joseph E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Dengue; Mutagenesis; Vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; FLAVIVIRUS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; RHESUS MONKEY; VIRUS REPLICATION; WILD TYPE;

3' UNTRANSLATED REGIONS; AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VIRUS; DNA, COMPLEMENTARY; HEPATOCYTES; MACACA MULATTA; MICE; MICE, SCID; PHENOTYPE; POINT MUTATION; VACCINES, SYNTHETIC; VERO CELLS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 4043141495     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.031     Document Type: Article

References (48)

1. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11(3):1998;480-496
2. Gubler D.J. The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future. Ann. Acad. Med. Singapore. 27(2):1998;227-234
3. Murgue B., Roche C., Chungue E., Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60(4):2000;432-438
4. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181(1):2000;2-9
5. Gubler D.J. Human arbovirus infections worldwide. Ann. N. Y. Acad. Sci. 951:2001;13-24
6. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65(5):2001;405-413
7. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E. Jr., Markoff L., Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77(2):2003;1653-1657
8. Whitehead S.S., Hanley K.A., Blaney J.E. Jr., Gilmore L.E., Elkins W.R., Murphy B.R. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine. 21:2003;4307-4316
9. Rice CM. Flaviviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology. Philadelphia: Lippincott-Raven; 1996. p. 931-59.
10. Kanesa-Thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 19:2001;3179-3188
11. Vaughn D.W., Hoke C.H. Jr., Yoksan S., Lachance R., Innis B.L., Rice R.M., et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 14(4):1996;329-336
12. Eckels K.H., Scott R.M., Bancroft W.H., Brown J., Dubois D.R., Summers P.L., et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33(4):1984;684-689
13. Edelman R., Tacket C.O., Wasserman S.S., Vaughn D.W., Eckels K.H., Dubois D.R., et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J. Infect. Dis. 170(6):1994;1448-1455
14. Kalayanarooj S., Vaughn D.W., Nimmannitya S., Green S., Suntayakorn S., Kunentrasai N., et al. Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176(2):1997;313-321
15. Kuo C.H., Tai D.I., Chang-Chien C.S., Lan C.K., Chiou S.S., Liaw Y.F. Liver biochemical tests and dengue fever. Am. J. Trop. Med. Hyg. 47(3):1992;265-270
16. Mohan B., Patwari A.K., Anand V.K. Hepatic dysfunction in childhood dengue infection. J. Trop. Pediatr. 46(1):2000;40-43
17. Wahid S.F., Sanusi S., Zawawi M.M., Ali R.A. A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever. Southeast Asian J. Trop. Med. Public Health. 31(2):2000;259-263
18. Blaney J.E. Jr., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in Vero cells or human liver cells and attenuated in mice. J. Virol. 75(20):2001;9731-9740
19. Blaney J.E. Jr., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 300(1):2002;125-139
20. Blaney J.E. Jr., Manipon G.G., Murphy B.R., Whitehead S.S. Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice. Arch. Virol. 148(5):2003;999-1006
21. Hanley K.A., Lee J.J., Blaney J.E. Jr., Murphy B.R., Whitehead S.S. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J. Virol. 76(2):2002;525-531
22. Blaney J.E. Jr., Manipon G.G., Firestone C.-Y., Johnson D.H., Hanson C.T., Murphy B.R., et al. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine. 21:2003;4317-4327
23. Hanley K.A., Manlucu L.R., Gilmore L.E., Blaney J.E., Hanson C.T., Murphy B.R., et al. A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology. 312(1):2003;222-232
24. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe J.E. Jr., Elkins W.R., Collins P.L., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73(2):1999;871-877
25. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72(3):1998;1762-1768
26. Juhasz K., Whitehead S.S., Boulanger C.A., Firestone C.Y., Collins P.L., Murphy B.R. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine. 17(11-12):1999;1416- 1424
27. Skiadopoulos M.H., Surman S.R., St. Claire M., Elkins W.R., Collins P.L., Murphy B.R. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology. 260(1):1999;125-135
28. Markoff L., Pang X., Houng H.S., Falgont B., Olsen R., Jones E., et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76(7):2002;3318-3328
29. Durbin A.P., McAuliffe J.M., Collins P.L., Murphy B.R. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology. 261(2):1999;319-330
30. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42(9):1982;3858-3863
31. Lai C.J., Zhao B.T., Hori H., Bray M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc. Natl. Acad. Sci. U.S.A. 88(12):1991;5139-5143
32. Men R., Bray M., Clark D., Chanock R.M., Lai C.J. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70(6):1996;3930-3937
33. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 298(1):2002;146-159
34. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66(3):2002;264-272
35. McKee K.T. Jr., Bancroft W.H., Eckels K.H., Redfield R.R., Summers P.L., Russell P.K. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am. J. Trop. Med. Hyg. 36(2):1987;435-442
36. Innis B.L., Eckels K.H., Kraiselburd E., Dubois D.R., Meadors G.F., Gubler D.J., et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J. Infect. Dis. 158(4):1988;876-880
37. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. New York: CAB International; 1997. p. 367-77.
38. An J., Kimura-Kuroda J., Hirabayashi Y., Yasui K. Development of a novel mouse model for dengue virus infection. Virology. 263(1):1999;70-77
39. Mosier D.E. Human xenograft models for virus infection. Virology. 271(2):2000;215-219
40. Lee E., Weir R.C., Dalgarno L. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology. 232(2):1997;281-290
41. Dunster L.M., Wang H., Ryman K.D., Miller B.R., Watowich S.J., Minor P.D., et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology. 261(2):1999;309-318
42. Puri B., Nelson W.M., Henchal E.A., Hoke C.H., Eckels K.H., Dubois D.R., et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J. Gen. Virol. 78(Pt 9):1997;2287-2291
43. Halstead S.B., Shotwell H., Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J. Infect. Dis. 128(1):1973;15-22
44. Halstead S.B., Shotwell H., Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128(1):1973;7-14
45. Marchette N.J., Halstead S.B., Falkler W.A. Jr., Stenhouse A., Nash D. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J. Infect. Dis. 128(1):1973;23-30
46. Skiadopoulos M.H., Tao T., Surman S.R., Collins P.L., Murphy B.R. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine. 18(5-6):1999;503-510
47. Pletnev A.G., Bray M., Hanley K.A., Speicher J., Elkins R. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J. Virol. 75(17):2001;8259-8267
48. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. U.S.A. 99(5):2002;3036-3041